



BIBCOL

Bharat Immunologicals & Biologicals Corporation Limited

CIN – L24232UP1989GOI010542 (A Govt. of India Undertaking)

Regd. Office: Vill. Chola, Bulandshahr (UP)-Pin 203203

Phone 9458096110, Tele-Fax -05732 238757

Email – sklalacs@yahoo.co.in Website- www.bibcol.com

No. BIB/CS/STO. EXCHA./33(3)/2021-22

15.08.2021

To,
The Listing Department
The Bombay Stock Exchange
Phiroze Jeejeebhoy Towers,
25, Dalal Street
Mumbai – 400 001.

Sub.: Submission of Limited Review Report on Unaudited Quarterly Financial Results for quarter ended June 2021 in compliance of SEBI LODR please.

Sir/ Madam,

It is submitted the Limited Reviewed Report on Unaudited Quarterly Financial Results for quarter ended on 30.06.2021 in compliance of SEBI LODR please. The Statutory Audit for Annual Accounts for the year ended 31.03.2021 is under process by Auditors appointed by Comptroller and Auditor General of India (C&AG).

Submitted for taking on record please.

Thanking you

(Sandip Kumar Lal)
General Manager/
Company Secretary



Limited Review Report

In case of M/s Bharat Immunologicals and Biologicals Corporation Limited

Date:- 31-07-2021

Review Report to the Shareholders of M/s Bharat Immunologicals and Biologicals Corporation Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s Bharat Immunologicals and Biologicals Corporation Limited** for the period ended 30th June 2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement

Date:- 31-07-2021

Place:- Delhi

Sanjana & Associates
Chartered Accountant



UDFN-21559855AAAAAD5612

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED

(CIN:- L24232UP1989GOI010542)

Part I

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30-06-2021
Selected Information for the Period Ended 30-06-2021

(INR in Lakh)

S. No	Particulars	3 Months Ended on 30-06-2021	Preceding 3 Months Ended on 31-03-2021	Corresponding 3 Months Ended in the previous year 30-06-2020	Previous Year Ended as on 31-03-2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME				
	a) Income from Operations	1,421.54	1,562.35	1,915.29	8,533.36
	b) Other Income	24.93	907.58	-58.17	983.19
	Total Revenue (1)	1,446.47	2,469.93	1,857.12	9,516.55
2	EXPENDITURE				
	a) Cost of Material Consumed	2,063.81	782.81	2,141.45	6,105.99
	b) Purchase of Stock in Trade	-	-	-	-
	c) Change in Inventory of Finished Goods, Work in Progress and Stock in Trade	-1,178.68	1,338.30	-760.94	2,014.53
	d) Employees Benefits	283.34	805.63	158.49	1,575.25
	e) Finance Cost	115.61	121.71	109.10	477.02
	f) Depreciations and Amortization Expense	5.89	5.91	5.92	23.67
	g) Other Expense	149.20	227.19	313.45	1,043.51
	Total Expense (2)	1,439.18	3,281.55	1,967.47	11,239.97
3	Profit/ (Loss) before exceptional items (1-2)	7.29	-811.62	-110.35	-1,723.42
4	Tax Expense				
	a) Current Tax	-	-	-	-
	b) Deferred Tax	-185.35	-158.24	-31.90	-415.50
5	Profit/ (Loss) from continuing Operations (3-4)	192.64	-653.38	-78.45	-1,307.92
6	Other Comprehensive Income/(Loss) (Net of Taxes)	-	-	-	-
7	Total Comprehensive Income/ (Loss) for the period (5+6)	192.64	-653.38	-78.45	-1,307.92
8	Paid Up Equity Share Capital (Face Value of INR 10/- each)	4,318.00	4,318.00	4,318.00	4,318.00
9	Earning Per Share (of INR 10/- each) not annualized				
	a) Basic	0.45	-1.51	-0.18	-3.03
	b) Diluted	0.45	-1.51	-0.18	-3.03

Note:- Refer our Note Separately



Sanj

Part II
Selected Information for the Period Ended 30-06-2021

S.No	Particulars	3 Months Ended on 30- 06-2021	Preceding 3 Months Ended on 31- 03-2021	Corresponding 3 Months Ended in the previous year 30-06-2020	Previous Year Ended as on 31-03-2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A1	PARTICULARS OF SHAREHOLDING				
	Public shareholding				
	- Number of Shares	1,75,94,000.00	1,75,94,000.00	1,75,94,000.00	1,75,94,000.00
	- Percentage of shareholding	40.75	40.75	40.75	40.75
A2	Promoters and Promoters Group shareholding				
	a) Pledged/ Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shareholding (as a% of the total share capital of the company)	-	-	-	-
	b) Non - encumbered				
	- Number of Shares	2,55,86,000.00	2,55,86,000.00	2,55,86,000.00	2,55,86,000.00
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shareholding (as a% of the total share capital of the company)	59.25	59.25	59.25	59.25
B	Particulars	3 Months ended (30/06/2021)			
	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter	NIL			
	Received during the quarter	NIL			
	Disposed of during the quarter	NIL			
	Remaining unresolved at the end of the quarter	-			



S. J.

Segment Reporting for the Period Ended 30-06-2021

(INR in Lakh)

S.No	Particulars	3 Months Ended on 30-06-2021	Preceding 3 Months Ended on 31-03-2021	Corresponding 3 Months Ended in the previous year 30-06-2020	Previous Year Ended as on 31-03-2021
1	SEGMENT REVENUE				
	Oral Polio Vaccine	1,419.58	1,561.42	1,912.00	8,525.15
	Zinc Dispersible Tablets	-	-	0.13	0.16
	BIB Sweet Tablets	0.02	-	-	0.01
	BIBSANIT	1.94	1.73	3.16	8.04
	Less: Inter segment revenue	-	-	-	-
	Net Sales/ Income from operations	1,421.54	1,563.15	1,915.29	8,533.36
2	SEGMENT RESULTS (Profit Before Tax)				
	Oral Polio Vaccine	192.37	-1164.95	-109.90	-2,409.02
	Zinc Dispersible Tablets	-	-0.44	-1.01	-5.11
	BIB Sweet Tablets	-	-	-	-
	BIBSANIT	0.27	1.55	0.56	-3.68
	Less: Unallocable expenditure net off unallocable Income	-	-	-	-
	Total Profit before Tax	192.64	-811.62	-110.35	-1,723.42
3	CAPITAL EMPLOYED (Segment Assets less Liabilities)				
	Oral Polio Vaccine	3,604.97	3,412.60	4,756.54	3,412.60
	Zinc Dispersible Tablets	-225.95	-8.72	-8.67	-710.39
	BIB Sweet Tablets	-	0.03	0.03	0.03
	BIBSANIT	19.60	-	-	-
	Others	36.40	-51.85	-144.78	-257.61
	Total Capital employed	1,810.77	853.51	4,603.12	4,170.09

Notes:-

1. The above Un-Audited results for the Quarter ended 30th June, 2021 have been review by the Audit Committee and were taken on record by the Board of Directors in their meeting held on July 22, 2021.
2. Valuation of Closing Stock has been done on the basis of Net realizable value.
3. In earlier quarters depreciation has been charged on the basis of Companies Act & balancing figure Has been taken in quarter 4 depreciation for the previous year ended 31.03.2021.
4. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rule 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
5. The format for unaudited quarterly results as prescribed in SEBI's Circular dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.


6. This statement does include Ind AS compliant results for the previous year ended 31.03.2021.



Seip.

7. Segment information as per Ind AS 108 has been given above as Segment Reporting.
The Company is currently engaged in production of Oral Polio Vaccine, Zinc Dispersible Tablets and Sweetener.
8. The Ind As complaint corresponding figures in the previous year have been subjected to audited. However, the company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
9. Previous year/quarter figures have been regrouped/re-arranged wherever necessary, to make it comparable.

Date :- 27.07.2021


(Chandra Prakash Goyal)
Managing Director

27.7.2021

Saip

